Research Article

Sodium Houttuynonate Ameliorates β-amyloid_{1-42}-Induced Memory Impairment and Neuroinflammation through Inhibiting the NLRP3/GSDMD Pathway in Alzheimer’s Disease

Yuequan Zhao,¹ YunPeng Tian,¹ and Tao Feng²

¹The Second Ward of Neurology Department, Dongying People’s Hospital, Dongying, Shandong 257091, China
²Department of Pharmacy, Dongying People’s Hospital, Dongying, Shandong 257091, China

Correspondence should be addressed to Tao Feng; fengtaoft34@126.com

Received 28 August 2020; Revised 26 January 2021; Accepted 18 May 2021; Published 4 June 2021

Objective. Our research is designed to explore the function of sodium houttuynate (SH) on Alzheimer’s disease (AD) and its potential molecular mechanisms.

Methods. In our study, the Morris water maze (MWM) test was used to assess the role of SH on spatial learning and memory deficiency in amyloid-β peptide (Aβ)_{1-42}-induced AD mice. We explored the functions of SH on proinflammatory cytokines, neuron apoptosis, and damage in vivo and in vitro by using an enzyme-linked immunosorbent assay (ELISA), quantitative real-time polymerase chain reaction (qRT-PCR), flow cytometry, western blot, and Nissl staining. Moreover, the effect of SH on oxidative stress in vivo and in vitro was also detected. To explore the underlying molecular mechanisms of SH on AD, the expressions of proteins and mRNA involved in the NOD-like receptor pyrin domain containing-3/gasdermin D (NLRP3/GSDMD) pathway were determined using western blot, immunofluorescence staining, and qRT-PCR.

Results. Our data demonstrated that SH ameliorated spatial learning and memory deficiency in Aβ_{1-42}-induced AD mice. Moreover, SH significantly improved hippocampal neuron damage and inhibited oxidative stress, neuroinflammation, and neuron apoptosis in Aβ_{1-42}-induced AD mice and PC12 cells. The results also revealed that SH protected Aβ_{1-42}-induced AD through inhibiting the NLRP3/GSDMD pathway.

Conclusion. The present study demonstrated that SH could ameliorate Aβ_{1-42}-induced memory impairment neuroinflammation and pyroptosis through inhibiting the NLRP3/GSDMD pathway in AD, suggesting that SH may be a potential candidate for AD treatment.

1. Introduction

Alzheimer’s disease (AD) is the most common neurodegenerative disease, which is mainly characterized by progressive cognitive impairment and irreversible memory loss [1, 2]. Recently, numerous studies have shown that the excessive production and deposition of amyloid-β peptides (Aβ) as senile plaques can initiate the process of neurodegeneration in AD [3, 4]. There is a newly diagnosed AD case every 3 sec all over the world [5]. However, current treatment and drug could not effectively terminate or reverse the progression of AD. Therefore, it is urgent to search new therapeutic methods and medicines for the treatment of AD.

Houttuynia cordata is a commonly used traditional Chinese herb and possesses a variety of pharmacological activities, including anti-inflammatory activity, antivirus activity, and antibacterial activity [6]. Decanoyl acetaldehyde (houttuynin) is one of the main extracts from Houttuynia cordata. At present, sodium houttuynonate (C_{12}H_{23}O_{5}SNa, SH) was synthesized by decanoyl acetaldehyde and sodium bisulfite as a result of the instability of decanoyl acetaldehyde [7]. A study by Huh et al. [8] has reported that Houttuynia cordata could significantly improve cognitive deficits in AD. However, the effect of SH on AD has not been reported.

NOD-like receptors (NLRs) are a kind of cytoplasmic sensors or receptors that play an important role in the process of neuroinflammation [9]. NOD-like receptor pyrin domain containing-3 (NLRP3) inflammasome, a member of the NLR family, is a multiprotein complex consisting of the core protein NLRP3 and regulatory molecules
pro-caspase-1 and apoptosis-associated speck-like protein (ASC). The activated NLRP3 inflammasome causes the cleavage of pro-caspase-1 into active caspase-1, which can induce the secretion of pro-inflammatory cytokines [10, 11] and cleaves gasdermin D (GSDMD) into N-terminal pore-forming domain (GSDMD-N) and the C-terminal repressor domain (GSDMD-C) [12]. Subsequently, GSDMD-N interacts with the cell membrane for forming pores. Meanwhile, pro-inflammatory cytokines flow out through the pores and then cause inflammatory responses causing pyroptosis [12, 13]. Pyroptosis is an inflammatory form of programmed cell death that is associated with inflammasome activation [14]. Recently, increasing evidence has confirmed that the inhibition of pyroptosis can significantly prevent the progression of AD [15]. In addition, neuroinflammation is reported to be an important factor in the pathological procession of neurodegenerative disease, especially AD [16]. In this study, we detected the function of SH on AD and further investigated whether the mechanism is related to the NLRP3/GSDMD pathway.

2. Materials and Methods

2.1. Preparation of Aβ Oligomer. A soluble Aβ oligomer was prepared as described by Xiang et al. [17]. Aβ_{1-42} was dissolved in sterile H_{2}O at a concentration of 1 mM, evaporated with high-purity N_{2} blowing at 37°C for 30 min, and then incubated for 48 h at room temperature to form the Aβ oligomer. Subsequently, the stock solution of Aβ_{1-42} was diluted in sterile phosphate-buffered saline (PBS) to the desired concentrations immediately before use.

2.2. Animals. Male ICR mice (6 weeks old, 25-30 g) were obtained from Vital River Experimental Technology Company (Beijing, China). All mice had free access to water and food and were maintained under a temperature of 22 ± 1°C, 60% humidity, and a 12 h light/dark cycle (lights on from 7:00 a.m. to 7:00 p.m.). Before the experiments, the animals were allowed to acclimate for seven days. The experimental protocol of our study was performed in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the ethics committee of our hospital.

2.3. Aβ_{1-42} Injection and Drug Administration. Fifty mice were randomly divided into five treatment groups with ten animals in each group: Control group, Aβ_{1-42} group, Aβ_{1-42} +SH (25 mg/kg) group, Aβ_{1-42} +SH (50 mg/kg) group, and Aβ_{1-42} +SH (100 mg/kg) group. Each mouse was anesthetized with intraperitoneal injection of pentobarbital sodium (40 mg/kg). Then, 3 μl Aβ_{1-42} (10 ng/μl) was stereotaxically injected into the hippocampus CA1 subregion in which the coordinates were as follows: -2.3 mm anterior/posterior, ±1.8 mm medial/lateral, and -1.75 mm dorsal/ventral from the bregma. In addition, the control group mice received the same volume of saline. From the second day after surgery, the mice in the Aβ_{1-42} +SH (25 mg/kg), Aβ_{1-42} +SH (50 mg/kg), and Aβ_{1-42} +SH (100 mg/kg) groups were administered by oral administration with corresponding doses once a day, while mice in the Control and Aβ_{1-42} groups were administered with the same volume of saline for 28 days.

2.4. Morris Water Maze (MWM) Test. The MWM test was used to evaluate the spatial learning and memory abilities of the mice. Simply, following the given SH for 28 consecutive days, each animal was subjected to finding the submerged platform through a daily acquisition test (4 trials per day). And the maximum trial length was 120 s. If a mouse did not locate the platform within 120 s, it was then guided to the platform and placed on the platform for 30 s. In this case, its escape latency was still marked as 120 s. This procedure lasted for 6 days, with two training sessions each day and a 15 min interval between the sessions. On the sixth day, the animals were subjected to a probe trial session in which the platform was removed from the pool and mice were allowed to search for it for 120 s. The escape latency, the time spent in the target quadrant, and the frequency of mice crossing the virtual platform were recorded and analyzed by using a video tracking system.

2.5. Nissl Staining. The brain tissues of the mice were removed and postfixed in 4% formaldehyde solution at room temperature for 24 h. Subsequently, the brain tissues were dehydrated in graded concentrations of ethanol and then embedded in paraffin and transversely cut into 5 μm thick sections. Then, the tissue sections were treated with conventional Nissl staining and visualized with an optical microscope (magnification, ×400).

2.6. Cell Culture and the Establishment of AD Model In Vitro. The rat pheochromocytoma (PC12) cell line was supplied by the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in a RPMI-1640 medium (Sigma, USA) containing 10% fetal bovine serum (FBS; Gibco, USA) and 1% antibiotics (HyClone, USA) and maintained at 37°C in a humidified incubator containing 5% CO_{2}.

For AD cell model in vitro, PC12 cells (1 × 10^4 cells/well) were planted into 96-well plates and cultured for 24 h. The PC12 cells were pretreated with SH (15, 30, 60, 120, and 240 μg/ml) or an inhibitor of NLRP3 inflammasome (Cyt09, 10 μM) for 2 h and then treated with Aβ_{1-42} (5 μM) for 24 h at 37°C.

2.7. Cell Viability. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to assess the cell viability. PC12 cells (1 × 10^5 cells/well) were planted into 96-well plates and cultured overnight. After treatment of SH or Aβ_{1-42}, 20 μl of MTT solution (5 mg/ml, Beyotime, Nanjing, China) was added to each well and incubated at 37°C for about 4 h. After removal of the MTT solution, PC12 cells were treated with 200 μl dimethyl sulfoxide (Beyotime) to dissolve the formazan crystals. Finally, the absorbance at 570 nm was recorded by using a microplate reader (Bio-Rad, USA).

2.8. Measurement of Reactive Oxygen Species (ROS), Malondialdehyde (MDA), and Superoxide Dismutase (SOD) Levels. To measure intracellular ROS level, PC12 cells
(2 × 10^5 cells/well) were plated into 6-well plates and cultured for 24 h. Following treatment of SH or Aβ1-42, PC12 cells were incubated with 10 nM fluorescent probe of 2′,7′-dichlorofluorescein diacetate (DCFH-DA, Sigma, USA) for 30 min at 37°C in the dark. The fluorescence signal was observed under a fluorescence microscope. In addition, the levels of SOD and MDA in both PC12 cells and brain tissues were measured by using the corresponding SOD and MDA detection kits (Beyotime) according to the manufacturer's instructions.

2.9. Flow Cytometry. The apoptosis of PC12 cells was assessed by using an Annexin V–fluorescein isothiocyanate/propiodium iodide (FITC/PI) apoptosis detection kit (KeyGen Biotech, Shanghai, China) according to the instructions of the manufacturer. In brief, after treatment of SH or Aβ1-42, PC12 cells were harvested and resuspended in a binding buffer. Afterwards, the cells were stained by Annexin V–FITC and PI in the dark for 20 min. Finally, the cell apoptosis was detected by flow cytometer.

2.10. Immunofluorescence Staining. PC12 cells were fixed in 4% paraformaldehyde solution at room temperature for 20 min and then blocked with 5% bovine serum albumin (BSA) in PBS for 30 minutes at room temperature. After that, the slices were incubated with rabbit anti-GSDMD antibody (1:100, #20770-1-AP, Proteintech, USA) and rabbit anti-NLRP3 antibody (1:200, #ab214185, Abcam, USA) overnight at 4°C. Following washed with PBS, the slices were incubated with Cy3-labeled goat anti-rabbit secondary antibody (1:500, Beyotime) for 1 h at 37°C in the dark. The cells were stained with 4′,6-diamidino-2-phenylindole (DAPI, Sigma, USA) for 10 min at room temperature. The fluorescence images were randomly scanned with a confocal laser scanning microscope (Nikon, Tokyo, Japan) by a single investigator who was blind to the sample identity.

2.11. Enzyme-Linked Immunosorbent Assay (ELISA). After treatment of SH or Aβ1-42, the levels of tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and interleukin-18 (IL-18) in both PC12 cells and brain tissues were detected by using their corresponding ELISA kits (R&D, USA) according to the instructions of the manufacturer.

2.12. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). To extract the total RNA from PC12 cells, a TRIzol reagent (Invitrogen, USA) was used following the manufacturer’s manual. Total RNA was reverse-transcribed into cDNA by using a GoScript™ Reverse Transcription System (Promega, USA). Then, qRT-PCR was performed using a GoTaq one-step real-time PCR kit (Promega). The primer sequences were supplied by the Shanghai Rui Jingsheng Biological Engineering Co., Ltd. and listed as follows: NLRP3 (sense): 5′-GCCATACGACTCCAGATAGTAGC-3′ and (antisense): 5′-GTGCCCCTACAACCTCTCTCTTG-3′; GAPDH (sense): 5′-GTCTCCACCTCTGCCCCGTAG-3′ and (antisense): 5′-CCACTCAGGGAATTTCAAC-3′; β-actin (sense): 5′-CCGTGGAGAAGACCAAGAGGAGT-3′ and (antisense): 5′-CCCCTGACAGGATGTCTCCA-3′; GSDMD (sense): 5′-GGCACACGGATGAGTCTTT-3′ and (antisense): 5′-CCGTGGAGAAGACCAAGAGGAGT-3′.

2.13. Western Blot Analysis. Total protein was extracted from PC12 cells and brain tissues by using a RIPA lysis buffer (Beyotime). Protein quantification was performed using the Bradford method. The proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes. After being blocked for 2 h in 5% nonfat dry milk, the membranes were incubated with the specific primary antibodies (Bcl-2, 1:1000, #12789-1-AP; Bax, 1:500, #15422-1-AP; caspase-3, 1:1000, #19677-1-AP; GSDMD, 1:500, #20770-1-AP; β-actin, 1:1000, #14395-1-AP; Proteintech, USA; NLRP3, 1:1000, #ab214185; ASC, 1:1000, #ab155970; caspase-1, 1:1000, #ab179515; Abcam, USA) overnight at 4°C. After being washed three times, the membranes were incubated with the horseradish peroxidase-conjugated secondary antibody (1:5000, Proteintech) for 2 hours at room temperature. Finally, the target proteins on the nitrocellulose membrane were visualized using the enhanced chemiluminescence (ECL) kit and captured using a Bio-Rad BioImaging System.

2.14. Statistical Analysis. All data were expressed as mean ± standard deviation and were analyzed by the SPSS22.0 software and GraphPad Prism 8.0 Software. One-way ANOVA combined with Turkey’s multiple comparison tests was used to compare data. P values less than 0.05 were considered statistically significant.

3. Results

3.1. SH Ameliorates Spatial Learning and Memory Deficiency in Aβ1-42-Induced AD Mice. The MWM test was used to evaluate the function of SH on the spatial learning and memory in mice. As shown in Figure 1(a), the escape latencies of the Control group, Aβ1-42 group, Aβ1-42+SH (25 mg/kg) group, Aβ1-42+SH (50 mg/kg) group, and Aβ1-42+SH (100 mg/kg) group were progressively decreased in successive trials. When compared with the Control group, the escape latency of the Aβ1-42 group was significantly increased at 6 days (P < 0.01). SH (25, 50, and 100 mg/kg) dramatically decreased the escape latency at 6 days in a dose-dependent manner (P < 0.01). In addition, the results of Figures 1(b) and 1(c) showed that mouse swimming time in the target quadrant and the frequency of platform crossing in the Aβ1-42 group were significantly decreased in comparison with those in the Control group (P < 0.01). The mice treated with SH (25, 50, and 100 mg/kg) spent more time in the target quadrant and increased the frequency of platform crossing relative to the mice in the Aβ1-42 group. In the subsequently experiments, SH (50 mg/kg) was used. All the results suggested that SH could ameliorate spatial learning and memory deficiency in Aβ1-42-induced AD mice.
3.2. SH Attenuates Aβ₁-42-Induced Hippocampal Alterations and Neuroinflammation in Mice.

We firstly assessed the effects of SH (50 mg/kg) on hippocampus neuron survival by using Nissl staining (Figure 2(a)). The shrinkage and loss of the neurons were found in mice of the Aβ₁-42 group relative to the Control group. When compared with the Aβ₁-42 group, the treatment of SH (50 mg/kg) dramatically restored the impairment of neuronal loss and shrinkage. As Figure 2(b) showed, the MDA level in Aβ₁-42 group brain tissues was significantly increased compared with that in the Control group (P < 0.01), while the SOD level was markedly decreased (P < 0.01). Treatment with SH (50 mg/kg) dramatically attenuated the role of Aβ₁-42 on MDA and SOD (P < 0.01). The ELISA assay (Figure 2(c)) was further used to detect the levels of TNF-α, IL-1β, IL-6, and IL-18 in brain tissues. The results showed that the levels of IL-6, IL-1β, IL-18, and TNF-α in the Aβ₁-42 group were higher than those in the Control group (P < 0.01). On the contrary, treating SH (50 mg/kg) significantly reduced the levels of IL-6, IL-1β, IL-18, and TNF-α compared with the Aβ₁-42 group (P < 0.01).

In addition, the results of the western blot (Figure 2(d)) revealed that the expressions of caspase-3 and Bax in Aβ₁-42 group brain tissues were significantly increased compared with those in the Control group (P < 0.01), while the Bcl-2 expression was markedly decreased (P < 0.01). Treatment with SH (50 mg/kg) dramatically attenuated the effect of Aβ₁-42 on the expressions of Bcl-2, Bax, and caspase-3 (P < 0.01). All the results indicated that SH (50 mg/kg) could attenuate Aβ₁-42-induced hippocampal alterations, oxidative stress, neuroinflammation, and neuronal apoptosis in mice.
3.3. SH Attenuates Aβ1-42-Induced Oxidative Stress and Cell Apoptosis in PC12 Cells. We explored the cytotoxic effect of SH on PC12 cell viability by using the MTT assay. The results showed that SH was not cytotoxic to PC12 cells in the concentration range of 0 μg/ml to 120 μg/ml (Figure 3(a)). In addition, the treatment with SH (15, 30, 60, and 120 μg/ml) significantly inhibited the Aβ1-42-induced cell death in a dose-dependent manner (P < 0.05, P < 0.01) (Figure 3(b)). And there was no significant difference in the rescue effect of SH (60 μg/ml) and SH (120 μg/ml). Therefore, SH (60 μg/ml) was chosen for the subsequent experiments. Then, we further investigated the effect of SH on Aβ1-42-induced oxidative stress and cell apoptosis in PC12 cells. As shown in Figures 3(c)–3(e), the levels of ROS and MDA in Aβ1-42
group PC12 cells were markedly elevated compared with those in the Control group ($P < 0.01$), but the SOD level was notably decreased ($P < 0.01$). Meanwhile, treating SH (60 μg/ml) significantly attenuated the effect of $A\beta_{1-42}$ on ROS, MDA, and SOD in PC12 cells ($P < 0.01$). Flow cytometry showed that $A\beta_{1-42}$ significantly promoted PC12 cell apoptosis ($P < 0.01$) (Figure 3(f)). The treatment of SH (60 μg/ml) dramatically reduced PC12 cell apoptosis when compared with the $A\beta_{1-42}$ group ($P < 0.01$) (Figure 3(f)). All data demonstrated that SH (60 μg/ml) could attenuate...
**Figure 4:** SH inhibited the expressions of inflammatory factors in Aβ1-42-induced PC12 cells. (a) The levels of IL-6, IL-1β, IL-18, and TNF-α were detected by ELISA. (b) The mRNA expressions of IL-6, IL-1β, IL-18, and TNF-α were detected by qRT-PCR. **P < 0.01, vs. the Control group; **P < 0.01, vs. the Aβ1-42 group.

Aβ1-42-induced oxidative stress and cell apoptosis in PC12 cells.

### 3.4. SH Inhibits the Expressions of Inflammatory Factors in Aβ1-42-Induced PC12 Cells

We investigated the effect of SH on the expressions of inflammatory factors in PC12 cells by using ELISA (Figure 4(a)) and qRT-PCR (Figure 4(b)). ELISA results showed that the levels of IL-6, IL-1β, IL-18, and TNF-α in the Aβ1-42 group were higher than those in the Control group (P < 0.01). Meanwhile, treating SH (60 μg/ml) significantly decreased the levels of IL-6, IL-1β, IL-18, and TNF-α in comparison with the Aβ1-42 group (P < 0.01). Besides, qRT-PCR results also demonstrated that the mRNA expressions of IL-6, IL-1β, IL-18, and TNF-α were increased in the Aβ1-42 group compared with the Control group (P < 0.01). Treating SH significantly attenuated the effect of Aβ1-42 on the mRNA expressions of IL-6, IL-1β, IL-18, and TNF-α in PC12 cells (P < 0.01). The results above suggested that SH could inhibit the expressions of inflammatory factors in Aβ1-42-induced PC12 cells.

### 3.5. SH Protects Aβ1-42-Induced AD through Inhibiting the NLRP3/GSDMD Pathway in PC12 Cells

As shown in Figures 5(a) and 5(b), the protein and mRNA expressions of NLRP3, ASC, caspase-1, and GSDMD-N were significantly increased in the Aβ1-42 group compared with the Control group (P < 0.01). Meanwhile, treating SH (60 μg/ml) dramatically decreased the protein and mRNA expressions of NLRP3, ASC, caspase-1, and GSDMD-N when compared with the Aβ1-42 group (P < 0.01). In addition, we evaluated the expression of NLRP3 and GSDMD-N in PC12 cells by immunofluorescence staining (Figures 5(c) and 5(d)). The results showed that the fluorescence intensities of NLRP3 and GSDMD-N were markedly higher in the Aβ1-42 group than the Control group, and these increases were notably attenuated by SH (60 μg/ml). The data indicated that SH might protect Aβ1-42-induced AD through inhibiting the NLRP3/GSDMD pathway in PC12 cells. To further verify the hypothesis above, CY-09 was used. The results of the western blot showed that the expressions of NLRP3, ASC, caspase-1, and GSDMD-N were significantly decreased in the Aβ1-42+CY-09 group compared with the Aβ1-42+SH group (P < 0.01) (Figure 6(a)). As Figure 6(b) showed, the levels of IL-6, IL-1β, IL-18, and TNF-α in the Aβ1-42+CY-09 group were lower than those in the Aβ1-42+SH group (P < 0.01). In addition, flow cytometry also revealed that PC12 cell apoptosis was markedly decreased in the Aβ1-42+CY-09 group in comparison with the Aβ1-42+SH group (P < 0.01) (Figure 6(c)). All the results demonstrated that SH (60 μg/ml) could protect Aβ1-42-induced AD through inhibiting the NLRP3/GSDMD pathway in PC12 cells.

### 4. Discussion

AD is a specific form of dementia in elderly people that affects more than 35 million individuals all over the world [18]. By 2050, the number of AD patients will increase to 135.46 million [19]. Although some progress has been made in the aspects of understanding the pathophysiology of AD, there are no effective treatments, and only a few medicines are currently available to patients. Thus, there is an urgent need to search innovative therapeutic strategies and effective drugs for the benefit of AD patients. In the present study, we confirmed that SH could ameliorate Aβ1-42-induced memory impairment, neuroinflammation, and pyroptosis through inhibiting the NLRP3/GSDMD pathway in AD.
4.1. Effect of SH on Cognitive Deficit and Memory Loss in AD Mice. The main pathological features of AD are progressive cognitive impairment and irreversible memory loss [20]. Huh et al. [8] have reported that *Houttuynia cordata* could significantly improve cognitive deficits of AD mice. Therefore, SH was selected in our study to investigate its effects on AD treatment. In the present study, MWM test results confirmed that SH significantly ameliorated spatial learning and memory deficiency in Aβ1-42-induced AD mice, suggesting that SH could improve cognitive deficits and memory loss in the progression of AD mice.

4.2. Effect of SH on Aβ1-42-Induced Neuroinflammation In Vivo and In Vitro. SH has been reported to have therapeutic effects on various diseases due to its anti-inflammatory activity and antibacterial activity [21–24]. Researchers have found that neuroinflammation plays a critical role in the progression of AD [25]. Singhal et al. have suggested that neuroinflammation is induced by the increased generation of inflammatory factors [26]. Demirci et al. have reported that the levels of proinflammatory cytokines (IL-6, IL-1β, IL-18, and TNF-α) in AD patients were higher than those in healthy volunteers [27]. In this study, we found that Aβ1-42 treatment significantly increased the levels of IL-6, IL-1β, IL-18, and TNF-α both in vivo and in vitro. SH significantly decreased the levels of IL-6, IL-1β, IL-18, and TNF-α in Aβ1-42-induced AD in vivo and in vitro. These data suggested that SH could prevent Aβ1-42-induced AD through inhibiting neuroinflammation.

4.3. Effect of SH on Aβ1-42-Induced Neuron Pyroptosis In Vivo and In Vitro. Galimberti and Scarpini [28] have reported that neuroinflammation is closely associated with neuronal apoptosis in AD. Neuronal apoptosis is identified to play an important role in learning and memory deficiency in AD [29]. In the present study, the results of the western blot

**Figure 5:** SH inhibited the NLRP3/GSDMD pathway in PC12 cells. (a) The protein expressions of NLRP3, ASC, caspase-1, and GSDMD-N were measured by western blot. (b) The mRNA expressions of NLRP3, ASC, caspase-1, and GSDMD-N were measured by qRT-PCR. (c) The expression of NLRP3 was determined by immunofluorescence staining. (d) The expression of GSDMD-N was determined by immunofluorescence staining. **∗∗P < 0.01, vs. the Control group; **##P < 0.01, vs. the Aβ1-42 group.**
showed that SH could increase Bcl-2 protein expression and inhibit protein expression of Bax and caspase-3 in Aβ1-42-induced AD in vivo and in vitro. Nissl staining results also demonstrated that SH could markedly attenuate hippocampal neural damage in Aβ1-42-induced AD mice. The data of flow cytometry showed that SH markedly inhibited Aβ1-42-induced apoptosis of PC12 cells. Besides, MTT results showed that SH significantly increased cell viability of Aβ1-

![Graph showing protein expression levels of NLRP3, ASC, Caspase-1, and GSDMD-N](image)

![Bar graph showing cytokine levels](image)

![Flow cytometry analysis](image)

**Figure 6:** CY-09 enhanced the inhibitory effects of SH on proinflammatory cytokines and cell apoptosis in PC12 cells. (a) The protein expressions of NLRP3, ASC, caspase-1, and GSDMD-N were measured by western blot. (b) The levels of IL-6, IL-1β, IL-18, and TNF-α were detected by ELISA. (c) PC12 cell apoptosis was detected by flow cytometry. **P < 0.01**, vs. the Aβ1-42 group; ##**P < 0.01**, vs. the Aβ1-42 +SH group.
NLRP3/GSDMD pathway, an inhibitor of NLRP3 in further verify whether SH could prevent AD through the activation of the NLRP3/GSDMD pathway in AD. Then, to in vitro induced AD through inhibiting oxidative stress. The data confirmed that SH could prevent $\beta_{1-42}$-induced AD through inhibiting oxidative stress.

4.4. Effect of SH on $\beta_{1-42}$-Induced Oxidative Stress In Vivo and In Vitro. Oxidative stress induced by ROS overproduction is considered to contribute to the pathogenesis of AD [30]. Therefore, we focused on ROS and the origin of oxidative stress via determining the levels of oxidative stress markers (MDA and SOD). In our study, we found that $\beta_{1-42}$ treatment remarkably increased the MDA level and decreased the ROS level in vivo and in vitro. SH treatment significantly inhibited the generation of ROS and MDA and promoted the SOD level in $\beta_{1-42}$-induced AD in vivo and in vitro. The data confirmed that SH could prevent $\beta_{1-42}$-induced AD through inhibiting oxidative stress.

4.5. Effect of SH on the NLRP3/GSDMD Pathway in $\beta_{1-42}$-Induced PC12 Cells. Recently, more and more studies have indicated that inflammasomes are closely related to neurodegenerative diseases: activated NLRP3 was observed in AD [31]. It is reported that NLRP3 inflammasome plays important roles in $\beta$-induced inflammation [32]. When NLRP3 inflammasome is activated, NLRP3 and ASC can cut procaspase-1 into active caspase-1 [33]. The active caspase-1 induces a secondary cascade of events associated to the releases of proinflammatory cytokines such as IL-1$\beta$ and IL-18 [10]. In addition, the active caspase-1 also cleaves GSDMD into GSDMD-N and GSDMD-C [12]. After that, inflammatory factors flow out from the cells through the pores caused by GSDMD-N, which further trigger an inflammatory response and cause pyroptosis [12]. Recently, increasing evidence has confirmed that the inhibition of pyroptosis can significantly prevent the progression of AD [15]. Our data showed that SH significantly decreased the expressions of NLRP3, ASC, caspase-1, and GSDMD-N in $\beta_{1-42}$-induced AD in vitro, suggesting that SH could inhibit the activation of the NLRP3/GSDMD pathway in AD. Then, to further verify whether SH could prevent AD through the NLRP3/GSDMD pathway, an inhibitor of NLRP3 inflammasome (CY-09) was used in our experiment. The results showed that the effects of SH on proinflammatory cytokines and cell apoptosis were enhanced by CY-09, indicating that SH could protect $\beta_{1-42}$-induced AD through inhibiting the NLRP3/GSDMD pathway.

The nosogenesis and progression of AD involve many factors. However, our present study was confined to exploring the mechanism of SH on the NLRP3/GSDMD pathway and oxidative stress. Whether SH can alleviate the symptoms of AD by other pathways remains to be further studied.

5. Conclusion

In summary, we demonstrated that SH could ameliorate $\beta_{1-42}$-induced memory impairment, neuroinflammation, and pyroptosis through inhibiting the NLRP3/GSDMD pathway in AD. The findings of our study reveal that SH could serve as a therapeutic approach for the treatment of AD. In the future, further study might be focused on other underlying mechanisms of SH on AD.

Data Availability

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Disclosure

Yuequan Zhao and YunPeng Tian are co-first authors.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Tao Feng designed the study; Yuequan Zhao and YunPeng Tian performed the research, analyzed the data, and wrote the paper.

References

[1] A. Vallée and Y. Lecarpentier, “Alzheimer disease: crosstalk between the canonical Wnt/beta-catenin pathway and PPARs alpha and gamma,” Frontiers in Neuroscience, vol. 10, p. 149, 2016.

[2] V. Solfrizzi, C. Custodero, M. Lozupone et al., “Relationships of dietary patterns, foods, and micro- and macronutrients with Alzheimer’s disease and late-life cognitive disorders: a systematic review,” Journal of Alzheimer’s Disease, vol. 59, no. 3, pp. 815–849, 2017.

[3] C. Shi, L. Zhang, and C. Qin, “Long non-coding RNAs in brain development, synaptic biology, and Alzheimer’s disease,” Brain Research Bulletin, vol. 132, pp. 166–169, 2017.

[4] H. A. Lashuel, D. Hartley, B. M. Petre, T. Walz, and P. T. Lansbury Jr., “Amyloid pores from pathogenic mutations,” Nature, vol. 418, no. 6895, p. 291, 2002.

[5] J. Coyle, D. Price, and M. DeLong, “Alzheimer’s disease: a disorder of cortical cholinergic innervation,” Science, vol. 219, no. 4589, pp. 1184–1190, 1983.

[6] Q. Zhu, X. Xu, X. Liu et al., “Sodium houttuynate inhibits inflammation by blocking the MAPKs/NF-kB signaling pathways in bovine endometrial epithelial cells,” Research in Veterinary Science, vol. 100, pp. 245–251, 2015.

[7] J. Shao, H. Cheng, C. Wang, and Y. Wang, “A Phytoanticipin Derivative, Sodium Houttuynate, Induces In Vitro Synergistic Effects with Levofloxacin against Biofilm Formation by Pseudomonas aeruginosa,” Molecules, vol. 17, no. 9, pp. 11242–11254, 2012.

[8] E. Huh, H. G. Kim, H. Park, M. S. Kang, B. Lee, and M. S. Oh, “Houttuynia cordata improves cognitive deficits in cholinergic dysfunction Alzheimer’s disease-like models,” Biomolecules & Therapeutics, vol. 22, no. 3, pp. 176–183, 2014.

[9] L. C. Freeman and J. P. Y. Ting, “The pathogenic role of the inflammasome in neurodegenerative diseases,” Journal of Neurochemistry, vol. 136, Supplement 1, pp. 29–38, 2016.
[10] M. Saresella, F. la Rosa, F. Piancone et al., “The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease,” Molecular Neurodegeneration, vol. 11, no. 1, p. 23, 2016.

[11] E. Latz, T. S. Xiao, and A. Stutz, “Activation and regulation of the inflammasomes,” Nature Reviews. Immunology, vol. 13, no. 6, pp. 397–411, 2013.

[12] H. Shi, Y. Zhang, J. Xing et al., “Baicalin attenuates hepatic injury in non-alcoholic steatohepatitis cell model by suppressing inflammasome-dependent GSDMD-mediated cell pyroptosis,” International Immunopharmacology, vol. 81, p. 106195, 2020.

[13] H. Guo, M. Xie, C. Zhou, and M. Zheng, “The relevance of pyroptosis in the pathogenesis of liver diseases,” Life Sciences, vol. 223, pp. 69–73, 2019.

[14] E. A. Miao, I. A. Leaf, P. M. Treuting et al., “Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria,” Nature Immunology, vol. 11, no. 12, pp. 1136–1142, 2010.

[15] N. Zhao, C. Sun, M. Zheng, S. Liu, and R. Shi, “Amentoflavone suppresses amyloid β1–42 neurotoxicity in Alzheimer’s disease through the inhibition of pyroptosis,” Life Sciences, vol. 239, p. 117043, 2019.

[16] I. López-González, A. Schlüter, E. Aso et al., “Neuroinflammatory signals in Alzheimer disease and APP/PS1 transgenic mice,” Journal of Neuropathology and Experimental Neurology, vol. 74, no. 4, pp. 319–344, 2015.

[17] S. Xiang, F. Liu, J. Lin et al., “Fucosanxin inhibits β-amyloid assembly and attenuates β-amyloid oligomer-induced cognitive impairments,” Journal of Agricultural and Food Chemistry, vol. 65, no. 20, pp. 4092–4102, 2017.

[18] H. W. Querfurth and F. M. LaFerla, “Alzheimer’s disease,” The New England Journal of Medicine, vol. 362, no. 4, pp. 329–344, 2010.

[19] L. Colucci, M. Bosco, A. M. Fasanaro, G. L. Gaeta, G. Ricci, and F. Amenta, “Alzheimer’s disease costs: what we know and what we should take into account,” Journal of Alzheimer’s Disease, vol. 42, no. 4, pp. 1311–1324, 2014.

[20] M. Crous-Bou, C. Minguillón, N. Gramunt, and J. L. Molinuevo, “Alzheimer’s disease prevention: from risk factors to early intervention,” Alzheimer’s Research & Therapy, vol. 9, no. 1, pp. 71–71, 2017.

[21] P. Pan, Y. J. Wang, L. Han, X. Liu, M. Zhao, and Y. F. Yuan, “Effects of sodium houttuyfonate on expression of NF-kappaB and MCP-1 in membranous glomerulonephritis,” Journal of Ethnopharmacology, vol. 131, no. 1, pp. 203–209, 2010.

[22] P. Liu, C. Yang, S. Lin et al., “Sodium houttuynate inhibits LPS-induced mastitis in mice via the NF-κB signalling pathway,” Molecular Medicine Reports, vol. 19, no. 3, pp. 2279–2286, 2019.

[23] Z. Wu, B. Tan, H. Zhang et al., “Effects of sodium houttuynofonate on pulmonary inflammation in COPD model rats,” Inflammation, vol. 40, no. 6, pp. 2109–2117, 2017.

[24] J. Shao, H. Cheng, C. Wang et al., “Sodium houttuynofonate, a potential phytoanticipin derivative of antibacterial agent, inhibits bacterial attachment and pyocyanine secretion of Pseudomonas aeruginosa by attenuating flagella-mediated swimming motility,” World Journal of Microbiology and Biotechnology, vol. 29, no. 12, pp. 2373–2378, 2013.

[25] X. Jin, M. Y. Liu, D. F. Zhang et al., “Baicalin mitigates cognitive impairment and protects neurons from microglia-mediated neuroinflammation via suppressing NLRP3 inflammasomes and TLR4/NF-κB signalling pathway,” CNS Neuroscience & Therapeutics, vol. 25, no. 5, pp. 575–590, 2019.

[26] G. Singhal, E. J. Jaehne, F. Corrigan, C. Toben, and B. T. Baune, “Inflammasomes in neuroinflammation and changes in brain function: a focused review,” Frontiers in Neuroscience, vol. 8, p. 315, 2014.

[27] S. Demirci, A. Aynal, K. Demirci, S. Demirci, and B. C. Ardoğan, “The serum levels of resistin and its relationship with other proinflammatory cytokines in patients with Alzheimer’s disease,” Clinical Psychopharmacology and Neuroscience, vol. 15, no. 1, pp. 59–63, 2017.

[28] D. Galimberti and E. Scarpini, “Inflammation and oxidative damage in Alzheimer’s disease: friend or foe?,” Frontiers in Bioscience, vol. 3, pp. 252–266, 2011.

[29] K. Heo, Y. J. Cho, K. J. Cho et al., “Minocycline inhibits caspase-dependent and -independent cell death pathways and is neuroprotective against hippocampal damage after treatment with kainic acid in mice,” Neuroscience Letters, vol. 398, no. 3, pp. 195–200, 2006.

[30] M. Valko, D. Leibfritz, J. Moncol, M. T. D. Cronin, M. Mazur, and J. Telser, “Free radicals and antioxidants in normal physiological functions and human disease,” The International Journal of Biochemistry & Cell Biology, vol. 39, no. 1, pp. 44–84, 2007.

[31] T. Ebrahimi, M. Rust, S. N. Kaiser et al., “α1-antitrypsin mitigates NLRP3 inflammasome activation in amyloid β1–42-stimulated murine astrocytes,” Journal of Neuroinflammation, vol. 15, no. 1, p. 282, 2018.

[32] B. R. Wang, J. Q. Shi, N. N. Ge et al., “PM2.5 exposure aggravates oligomeric amyloid beta-induced neuronal injury and promotes NLRP3 inflammasome activation in an in vitro model of Alzheimer’s disease,” Journal of Neuroinflammation, vol. 15, no. 1, p. 132, 2018.

[33] M. S. Tan, J. T. Yu, T. Jiang, X. C. Zhu, and L. Tan, “The NLRP3 inflammasome in Alzheimer’s disease,” Molecular Neurobiology, vol. 48, no. 3, pp. 875–882, 2013.